Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ENFN Stock Summary
Top 10 Correlated ETFs
ENFN
In the News
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
Finding undervalued stocks is one of the key elements to making successful investments. Undervalued stocks are those that trade below their intrinsic value, meaning that the market has not fully recognized their “true potential.
Enfusion, Inc. (ENFN) Q4 2023 Earnings Call Transcript
Enfusion, Inc. (ENFN) Q4 2023 Earnings Call Transcript
Enfusion, Inc. (ENFN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Enfusion, Inc. (ENFN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Enfusion, Inc. (ENFN) Lags Q4 Earnings Estimates
Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
Enfusion: Product Is Sticky And Industry Is Huge
I am recommending a buy rating as I see room for ENFN to grow and visible catalysts for growth acceleration. The company provides an end-to-end SaaS solution for investment managers, making it a sticky product with high pricing power. The industry is large and healthy, with ample opportunities for Enfusion to expand its market share.
Enfusion, Inc. (ENFN) Q3 2023 Earnings Call Transcript
Enfusion, Inc. (NYSE:ENFN ) Q3 2023 Results Conference Call November 7, 2023 8:30 AM ET Company Participants Ignatius Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Michael Infante - Morgan Stanley Faith Brunner - William Blair Elyse Kanner - JPMorgan Parker Lane - Stifel Crispin Love - Piper Sandler Callie Valenti - Goldman Sachs Natalie Howe - Bank of America Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Enfusion's Third Quarter 2023 Earnings Conference Call.
Enfusion: Still Bullish Considering Q3 EBITDA Beat
Enfusion's EBITDA expanded by +48% YoY in Q3 2023, which was +6% better than what the market had expected. ENFN's long-term prospects are favorable, taking into account the room for revenue growth and profit margin improvement. I retain a Buy rating for ENFN stock, in consideration of its good recent quarterly results and positive financial outlook.
Enfusion, Inc. (ENFN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Enfusion, Inc. (ENFN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The 3 Most Undervalued Under-$10 Stocks to Buy in September 2023
Finding undervalued stocks is one of the key strategies for successful investing. Undervalued stocks are those that trade below their intrinsic value, meaning that the market has not fully recognized their “true potential.
Enfusion, Inc. (ENFN) Q2 2023 Earnings Call Transcript
Enfusion, Inc. (NYSE:ENFN ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Iggy Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Kevin McVeigh - Credit Suisse Parker Lane - Stifel James Faucette - Morgan Stanley Callie Valenti - Goldman Sachs Dylan Becker - William Blair Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Enfusion Second Quarter 2023 Earnings Conference Call.
ENFN Financial details
ENFN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.92 | 1.24 | 1.35 | 1.76 | 1.35 | |
Net income per share | 0.2 | 0.06 | -3.4 | -0.16 | 0.05 | |
Operating cash flow per share | 0.19 | 0.03 | 0 | 0.17 | 0.19 | |
Free cash flow per share | 0.12 | -0.05 | -0.1 | 0.07 | 0.11 | |
Cash per share | 0.09 | 0.22 | 0.78 | 0.73 | 0.28 | |
Book value per share | -1.84 | -3.65 | 0.67 | 0.76 | 0.41 | |
Tangible book value per share | -1.84 | -3.65 | 1.17 | 1.21 | 0.6 | |
Share holders equity per share | -1.84 | -3.65 | 0.67 | 0.76 | 0.41 | |
Interest debt per share | 0.44 | 1.56 | 0.06 | 0.09 | 0.13 | |
Market cap | 1.27B | 1.27B | 1.74B | 825.75M | 1.26B | |
Enterprise value | 1.29B | 1.35B | 1.67B | 770.19M | 1.24B | |
P/E ratio | 100.28 | 312.53 | -6.16 | -62.26 | 208.38 | |
Price to sales ratio | 21.5 | 15.95 | 15.57 | 5.49 | 7.19 | |
POCF ratio | 103.13 | 762.26 | -5.47K | 58.33 | 51.28 | |
PFCF ratio | 161.12 | -372.95 | -208.71 | 132.65 | 84.76 | |
P/B Ratio | -10.77 | -5.43 | 31.45 | 12.7 | 23.39 | |
PTB ratio | -10.77 | -5.43 | 31.45 | 12.7 | 23.39 | |
EV to sales | 21.87 | 17.01 | 14.99 | 5.12 | 7.08 | |
Enterprise value over EBITDA | 85.93 | 160.27 | -6.13 | -137.05 | 60.16 | |
EV to operating cash flow | 104.9 | 813.09 | -5.27K | 54.41 | 50.46 | |
EV to free cash flow | 163.89 | -397.82 | -200.98 | 123.73 | 83.4 | |
Earnings yield | 0.01 | 0 | -0.16 | -0.02 | 0 | |
Free cash flow yield | 0.01 | 0 | 0 | 0.01 | 0.01 | |
Debt to equity | -0.23 | -0.42 | 0 | 0.11 | 0.29 | |
Debt to assets | 1.19 | 2.52 | 0 | 0.06 | 0.14 | |
Net debt to EBITDA | 1.45 | 10.02 | 0.24 | 9.89 | -0.98 | |
Current ratio | 2 | 2.71 | 11.06 | 5.57 | 3.44 | |
Interest coverage | 19.16 | 3.65 | -60.05 | -28.97 | 7.28 | |
Income quality | 0.97 | 0.41 | 0 | -1.07 | 3.87 | |
Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.87 | 1.14 | -0.01 | 0 | 0 | |
Sales general and administrative to revenue | 0.28 | 0.45 | 1.35 | 0.46 | 0.37 | |
Research and developement to revenue | 0.07 | 0.08 | 1.37 | 0.11 | 0.11 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.36 | -3.04 | 25.2 | -0.56 | -0.4 | |
Capex to revenue | -0.08 | -0.06 | -0.07 | -0.05 | -0.06 | |
Capex to depreciation | -3.83 | -2.21 | -2.02 | -1.25 | -1.13 | |
Stock based compensation to revenue | 0 | 0 | 2.59 | 0.17 | 0.04 | |
Graham number | 2.86 | 2.28 | 7.14 | 1.63 | 0.66 | |
ROIC | -0.15 | -0.04 | -5 | -0.16 | 0.12 | |
Return on tangible assets | 0.55 | 0.1 | -2.66 | -0.11 | 0.06 | |
Graham Net | -2 | -3.9 | 0.84 | 0.76 | 0.19 | |
Working capital | 8.1M | 18.26M | 81.57M | 79.43M | 49.54M | |
Tangible asset value | -117.88M | -233.56M | 97.44M | 103.44M | 77.48M | |
Net current asset value | -124.91M | -243.75M | 81.03M | 76.47M | 38.36M | |
Invested capital | -0.23 | -0.42 | 0 | 0.11 | 0.29 | |
Average receivables | 0 | 10.58M | 15.2M | 22.04M | 26.96M | |
Average payables | 0 | 463.5K | 1.51M | 2.11M | 1.95M | |
Average inventory | 0 | 0.5 | 0.5 | 3.05M | 3.05M | |
Days sales outstanding | 55.5 | 55.88 | 59.55 | 62.77 | 58.7 | |
Days payables outstanding | 9.53 | 8.27 | 28.98 | 13.06 | 14.01 | |
Days of inventory on hand | 0 | 0 | 0 | 47.31 | 0 | |
Receivables turnover | 6.58 | 6.53 | 6.13 | 5.82 | 6.22 | |
Payables turnover | 38.29 | 44.13 | 12.6 | 27.95 | 26.06 | |
Inventory turnover | 16.96M | 0 | 31.85M | 7.71 | 0 | |
ROE | -0.11 | -0.02 | -5.1 | -0.2 | 0.11 | |
Capex per share | -0.07 | -0.08 | -0.1 | -0.09 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.47 | 0.31 | 0.33 | 0.35 | 0.36 | |
Net income per share | 0.01 | 0.04 | 0 | 0.01 | 0 | |
Operating cash flow per share | 0.09 | 0.01 | 0.05 | 0.09 | 0.04 | |
Free cash flow per share | 0.07 | -0.01 | 0.03 | 0.07 | 0.02 | |
Cash per share | 0.73 | 0.41 | 0.21 | 0.25 | 0.28 | |
Book value per share | 0.76 | 0.48 | 0.37 | 0.4 | 0.42 | |
Tangible book value per share | 1.21 | 0.75 | 0.56 | 0.57 | 0.61 | |
Share holders equity per share | 0.76 | 0.48 | 0.37 | 0.4 | 0.42 | |
Interest debt per share | 0.09 | 0.11 | 0.1 | 0.13 | 0.12 | |
Market cap | 825.75M | 1.39B | 1.46B | 1.15B | 1.24B | |
Enterprise value | 770.19M | 1.35B | 1.44B | 1.13B | 1.22B | |
P/E ratio | 261.98 | 74.01 | 579.09 | 156.83 | 497.32 | |
Price to sales ratio | 20.38 | 33.92 | 34.1 | 25.85 | 26.66 | |
POCF ratio | 109.79 | 1.5K | 242.1 | 94.72 | 228.03 | |
PFCF ratio | 142.99 | -854.63 | 383.52 | 120.72 | 394.69 | |
P/B Ratio | 12.7 | 21.81 | 30.27 | 22.6 | 23.09 | |
PTB ratio | 12.7 | 21.81 | 30.27 | 22.6 | 23.09 | |
EV to sales | 19.01 | 32.92 | 33.75 | 25.51 | 26.23 | |
Enterprise value over EBITDA | 247.65 | 206 | 318.47 | 213.95 | 286.93 | |
EV to operating cash flow | 102.41 | 1.46K | 239.62 | 93.47 | 224.32 | |
EV to free cash flow | 133.37 | -829.45 | 379.58 | 119.13 | 388.27 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0.01 | 0 | 0 | 0.01 | 0 | |
Debt to equity | 0.11 | 0.21 | 0.27 | 0.33 | 0.29 | |
Debt to assets | 0.06 | 0.11 | 0.14 | 0.16 | 0.14 | |
Net debt to EBITDA | -17.86 | -6.25 | -3.3 | -2.87 | -4.75 | |
Current ratio | 5.57 | 6.32 | 4.33 | 3.79 | 3.44 | |
Interest coverage | 3.24 | 3.5 | 0 | 0 | 0 | |
Income quality | 9.54 | 0.2 | 6.03 | 4.55 | 8.52 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.37 | 0.35 | 0.38 | 0.38 | 0.37 | |
Research and developement to revenue | 0.12 | 0.11 | 0.1 | 0.11 | 0.13 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.23 | -2.76 | -0.37 | -0.22 | -0.42 | |
Capex to revenue | -0.04 | -0.06 | -0.05 | -0.06 | -0.05 | |
Capex to depreciation | -1.03 | -1.37 | -1.07 | -1.03 | -1.09 | |
Stock based compensation to revenue | 0.1 | -0.03 | 0.06 | 0.06 | 0.07 | |
Graham number | 0.4 | 0.62 | 0.2 | 0.36 | 0.21 | |
ROIC | 0.01 | 0.05 | 0.03 | 0.03 | 0.01 | |
Return on tangible assets | 0.01 | 0.04 | 0.01 | 0.02 | 0.01 | |
Graham Net | 0.76 | 0.4 | 0.21 | 0.19 | 0.2 | |
Working capital | 79.43M | 72.94M | 45.87M | 45.67M | 49.54M | |
Tangible asset value | 103.44M | 99.15M | 72.24M | 73.28M | 77.48M | |
Net current asset value | 76.47M | 64.3M | 37.82M | 33.58M | 38.36M | |
Invested capital | 0.11 | 0.21 | 0.27 | 0.33 | 0.29 | |
Average receivables | 27.42M | 25.11M | 24.76M | 25.01M | 26.46M | |
Average payables | 1.44M | 1.49M | 1.08M | 1.1M | 1.78M | |
Average inventory | 4.36M | 5.85M | 5.28M | 4.52M | 2.04M | |
Days sales outstanding | 57.43 | 53.5 | 53.03 | 50.43 | 54.34 | |
Days payables outstanding | 11.41 | 8.73 | 5.5 | 8.32 | 12.74 | |
Days of inventory on hand | 41.32 | 37.89 | 31.46 | 25.31 | 0 | |
Receivables turnover | 1.57 | 1.68 | 1.7 | 1.78 | 1.66 | |
Payables turnover | 7.89 | 10.31 | 16.37 | 10.82 | 7.06 | |
Inventory turnover | 2.18 | 2.38 | 2.86 | 3.56 | 0 | |
ROE | 0.01 | 0.07 | 0.01 | 0.04 | 0.01 | |
Capex per share | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
ENFN Frequently Asked Questions
What is Enfusion, Inc. stock symbol ?
Enfusion, Inc. is a US stock , located in Chicago of Il and trading under the symbol ENFN
What is Enfusion, Inc. stock quote today ?
Enfusion, Inc. stock price is $9.25 today.
Is Enfusion, Inc. stock public?
Yes, Enfusion, Inc. is a publicly traded company.